Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study

被引:0
作者
Kirstein, LM
Greenblatt, RM
Anastos, K
Levine, A
French, AL
Minkoff, H
Silver, S
Gange, SJ
机构
[1] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA
[2] Montefiore Med Ctr, Bronx, NY 10467 USA
[3] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[4] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA USA
[5] Univ So Calif, Sch Med, Dept Med, Los Angeles, CA USA
[6] Rush Med Coll, Cook County Hosp, Dept Med, Chicago, IL USA
[7] Maimonides Hosp, Dept Obstet & Gynecol, Brooklyn, NY USA
[8] SUNY, Hlth Sci Ctr, Brooklyn, NY USA
[9] George Washington Univ, Med Ctr, Washington, DC USA
关键词
HAART; antiretroviral therapy; switching; modification; discontinuation;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: The purpose of this study was to describe the variability in highly active antiretroviral therapy (HAART) regimens over time. the extent to which individuals switch. and the characteristics of those who are switching. Methods: We evaluated data collected between 1994 and 2000 from 1056 HIV-positive women enrolled in the Women's Interagency HIV Study (WIHS) who reported initiating HAART. We described the variability and prevalence of changes in HAART regimens between semiannual visits, estimated time to switch using Kaplan-Meier methods, investigated factors associated with a first switch using Cox proportional hazards models. and compared disease markers among women switching or remaining on unchanged HAART regimens. Results: We demonstrated a 13-fold increase in the number of unique HAART regimens reported since mid-1996 and showed that the amount of time spent on the first, second, or third regimen is similar. with an 8-month median time to switching or discontinuing the initial HAART regimen. Women who switched had a lower mean CD4 cell count and were more likely to have HIV RNA levels greater than 400 copies/mL. Overall, the percentage of women switching decreased over the course of follow-up (to 37% in September 2000), although the percentage discontinuing therapy altogether increased 2-fold. Conclusion: Our findings on the relatively high rate of HAART switching emphasize the complexity of managing and evaluating these therapies.
引用
收藏
页码:495 / 503
页数:9
相关论文
共 30 条
  • [21] Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study
    Ledergerber, B
    Egger, M
    Opravil, M
    Telenti, A
    Hirschel, B
    Battegay, M
    Vernazza, P
    Sudre, P
    Flepp, M
    Furrer, H
    Francioli, P
    Weber, R
    [J]. LANCET, 1999, 353 (9156) : 863 - 868
  • [22] Potential factors affecting adherence with HIV therapy
    Mehta, S
    Moore, RD
    Graham, NMH
    [J]. AIDS, 1997, 11 (14) : 1665 - 1670
  • [23] Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre
    Mocroft, A
    Youle, M
    Moore, A
    Sabin, CA
    Madge, S
    Lepri, AC
    Tyrer, M
    Chaloner, C
    Wilson, D
    Loveday, C
    Johnson, MA
    Phillips, AN
    [J]. AIDS, 2001, 15 (02) : 185 - 194
  • [24] Distinguishing efficacy, individual effectiveness and population effectiveness of therapies
    Muñoz, A
    Gange, SJ
    Jacobson, LP
    [J]. AIDS, 2000, 14 (06) : 754 - 756
  • [25] Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
    Palella, FJ
    Delaney, KM
    Moorman, AC
    Loveless, MO
    Fuhrer, J
    Satten, GA
    Aschman, DJ
    Holmberg, SD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (13) : 853 - 860
  • [26] Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe -: Results from the EuroSIDA Study
    Paredes, R
    Mocroft, A
    Kirk, O
    Lazzarin, A
    Barton, SE
    van Lunzen, J
    Katzenstein, TL
    Antunes, F
    Lundgren, JD
    Clotet, B
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (08) : 1123 - 1132
  • [27] SAAG MS, 1998, 12 WORLD AIDS C GEN
  • [28] Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: Prospective assessment with implications for enhancing compliance
    Singh, N
    Squier, C
    Sivek, C
    Wagener, M
    Nguyen, MH
    Yu, VL
    [J]. AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 1996, 8 (03): : 261 - 269
  • [29] Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants
    van Roon, EN
    Verzijl, JM
    Juttmann, JR
    Lenderink, AW
    Blans, MJ
    Egberts, ACG
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1999, 20 (03): : 290 - 294
  • [30] Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study
    Yamashita, TE
    Phair, JP
    Muñoz, A
    Margolick, JB
    Detels, R
    O'Brien, SJ
    Mellors, JW
    Wolinsky, SM
    Jacobson, LP
    [J]. AIDS, 2001, 15 (06) : 735 - 746